Pomerantz Law Firm Launches Investigation into SELLAS Life Sciences Group Alleged Securities Fraud
News provided bySELLAS Life Sciences Group, Inc · 1 min read
NEW YORK, Sept. 3, 2026 /CourierPR/ -- Pomerantz Law Firm Launches Investigation into Alleged Securities Fraud at SELLAS Life Sciences Group, Inc.
The investigation stems from a recent report on August 28, 2026, that SELLAS's phase 3 clinical trial for Galinpepimut-S (GPS) had reached its 80th patient death, a pre-specified event intended to trigger the release of clinical trial results. However, as of the report date, SELLAS had not released these results, prompting a sharp drop in its stock price.
According to the report, SELLAS's stock fell $2.00 per share, or 13.15%, closing at $13.21 per share. This significant drop in stock price has raised concerns among investors about potential mismanagement or fraudulent practices within the company.
Pomerantz Law Firm, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as one of the leading firms in corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, the firm has a long history of representing victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. Over the past 85 years, Pomerantz has secured numerous multimillion-dollar damages awards on behalf of its clients.
The firm's investigation is part of its ongoing commitment to protect the interests of investors and ensure transparency in corporate practices. Investors who believe they may have been affected by these alleged irregularities are encouraged to contact Pomerantz Law Firm for further guidance.